Evommune (NYSE:EVMN) CEO Luis Pena Sells 7,438 Shares

Evommune, Inc. (NYSE:EVMN) CEO Luis Pena sold 7,438 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the transaction, the chief executive officer owned 630,458 shares in the company, valued at approximately $14,317,701.18. This trade represents a 1.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Evommune Price Performance

Shares of EVMN stock traded down $0.72 on Wednesday, hitting $23.53. The company’s stock had a trading volume of 1,043,288 shares, compared to its average volume of 453,427. The stock has a market capitalization of $847.59 million and a price-to-earnings ratio of -2.48. Evommune, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $33.20. The firm’s fifty day moving average price is $23.14 and its 200-day moving average price is $22.27.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Analysts predict that Evommune, Inc. will post -2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Evommune

Several large investors have recently made changes to their positions in EVMN. Strs Ohio bought a new stake in Evommune during the 1st quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. bought a new position in Evommune in the 4th quarter worth approximately $34,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Evommune by 25.3% during the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company’s stock worth $295,000 after buying an additional 2,587 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Evommune during the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Evommune in the fourth quarter valued at approximately $335,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EVMN. Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price objective on shares of Evommune in a report on Friday, April 10th. Stifel Nicolaus started coverage on Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price target on the stock. Oppenheimer assumed coverage on shares of Evommune in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target on the stock. Morgan Stanley boosted their price objective on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Evommune in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $49.25.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.